

Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-29 cancelled

30 (Currently Amended). A method for treating a disease, disorder or injury in an organ which is susceptible to a T-cell-mediated specific autoimmune disease, wherein said ~~organ-disease~~ disease, disorder or injury is other than an autoimmune disease, the method comprising immunizing an individual having such a disease, disorder or injury with an agent selected from the group consisting of:

(a) a pathogenic self-antigen associated with a T-cell-mediated specific autoimmune disease of said organ;

(b) a peptide, ~~which the sequence of which is~~ comprised within the sequence of said pathogenic self-antigen of (a);

(c) a peptide obtained by modification of the peptide of (b), which modification consists in the replacement of one or more amino acid residues of the peptide by different amino acid residues, said modified peptide still being capable of recognizing the T-cell receptor recognized by the parent peptide but with less affinity (hereinafter "modified peptide");

(d) a nucleotide sequence encoding a pathogenic self-antigen of (a), a peptide of (b), or a modified peptide of (c) ; and

(e) T cells activated by a pathogenic self-antigen of (a), a peptide of (b), or a modified peptide of (c).

31 (Currently Amended). The method of claim 30, wherein said disease, disorder or injury is a non-autoimmune disease, disorder or injury of the eye and said pathogenic self-antigen is associated with a T-cell-mediated eye-specific autoimmune disease.

32 (Currently Amended). The method of claim 31, wherein said pathogenic self-antigen is an uveitogenic antigen associated with autoimmune uveitis.

33 (Currently Amended). The method of claim 32, wherein said pathogenic uveitogenic antigen is selected from the group consisting of interphotoreceptor retinoid-binding protein (IRBP), S-antigen (S-Ag) and rhodopsin.

34 (Withdrawn/Currently Amended). The method of claim 33, wherein said pathogenic uveitogenic antigen is IRBP and said agent is selected from the group consisting of:

(a) ~~interphotoreceptor retinoid-binding protein~~
~~(IRBP)~~ IRBP;

(b) a peptide, which the sequence of which is
comprised within the sequence of IRBP;

(c) a peptide obtained by modification of the
peptide of (b), which modification consists in the replacement
of one or more amino acid residues of the peptide by different
amino acid residues, said modified peptide still being capable
of recognizing the T-cell receptor recognized by the parent
peptide but with less affinity (hereinafter "modified
peptide");

(d) a nucleotide sequence encoding IRPB, a peptide
of (b), or a modified peptide of (c); and

(e) T cells activated by an agent selected from the
group consisting of IRPB, a peptide of (b), and a modified
peptide of (c).

35 (Withdrawn/Currently Amended). The method of
claim 34, wherein said agent is a peptide (b), which the
sequence of which is comprised within the sequence of IRBP, wherein said agent
is selected from the group consisting of
the peptides:

ADGSSWEGVGVVPDV (SEQ ID NO:1);

PTARSVGAADGSSWEGVGVVPDV (SEQ ID NO:2); and

HVDDTDLYLTIPTARSVGAADGS (SEQ ID NO:3).

36 (Currently Amended). The method of claim 33,
wherein said pathogenic uveitogenic antigen is S-AgS-Antigen
and said agent is selected from the group consisting of:

- (a) S-AgS-antigen (~~S-Ag~~);
- (b) a peptide, which the sequence of which is
comprised within the sequence of S-Ag;
- (c) a peptide obtained by modification of the
peptide of (b), which modification consists in the replacement
of one or more amino acid residues of the peptide by different
amino acid residues, said modified peptide still being capable
of recognizing the T-cell receptor recognized by the parent
peptide but with less affinity (hereinafter "modified
peptide");
- (d) a nucleotide sequence encoding S-Ag, a peptide
of (b), or a modified peptide of (c) ; and
- (e) T cells activated by an agent selected from the
group consisting of S-Ag, a peptide of (b), and a modified
peptide of (c).

37 (Withdrawn/Currently Amended). The method of
claim 36, wherein said agent is a peptide (b), which the
sequence of which is comprised within the sequence of S-Ag,
wherein said agent is selected from the group consisting of
the peptides:

TSSEVATE (SEQ ID NO:4);

DTNLASST (SEQ ID NO:6);
DTNLASSTIIKEGIDKTV (SEQ ID NO:8);
VPLLANNRERRGIALDGKIKHE (SEQ ID NO:9);
TSSEVATEVPFRLMHPQPED (SEQ ID NO:10);
SLTKTLTLVPLLANNRERRG (SEQ ID NO:11);
SLTRTLTLLPLLANNRERAG (SEQ ID NO:12);
KEGIDKTVMGILVSYQIKVKL (SEQ ID NO:13); and
KEGIDRTVLGILVSYQIKVKL (SEQ ID NO:14).

38 (Currently Amended). The method of claim 36,
wherein said agent is a modified peptide (c) ~~is~~ selected from
the group consisting of the peptides:

TSSEAATE (SEQ ID NO:5); and
DTALASST (SEQ ID NO:7).

39 (Previously Presented). The method of claim 31
for treating a disease, disorder or injury in the eye, wherein
said eye disease, disorder or injury is other than an
autoimmune disease.

40 (Withdrawn/Currently Amended). The method of
claim 39, wherein said non-autoimmune eye disease, disorder or
injury is blunt trauma caused by an ~~agent~~ agency selected from
the group consisting of a foreign bodies ~~body~~, contusion,
laceration, ~~burns~~ burn or laser surgery.

41 (Withdrawn/Currently Amended). The method of
claim 39, wherein said non-autoimmune eye disease, disorder or

Appln. No. 10,509,180
Amdt. dated July 12, 2007
Reply to Office action of June 12, 2007

injury is selected from the group consisting of a conjunctival, a corneal, a retinal, and an optic nerve or optic pathway disorder.

42 (Currently Amended). The method of claim 39,
wherein said non-autoimmune eye disease, disorder or injury is glaucoma.